Last update 28 May 2025

Elritercept

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
KER-050, TAK-226
Target
Action
modulators
Mechanism
ACVR2A modulators(activin A receptor type 2A modulators)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Transfusion dependent anaemiaPhase 3
United States
01 May 2025
Transfusion dependent anaemiaPhase 3
United Kingdom
01 May 2025
Myelodysplastic SyndromesPhase 3
United States
01 May 2025
Myelodysplastic SyndromesPhase 3
United Kingdom
01 May 2025
myelodysplastic anemiaPhase 2
China
14 Nov 2024
myelodysplastic anemiaPhase 2
China
14 Nov 2024
Post-essential thrombocythemia myelofibrosisPhase 2
United States
16 Dec 2021
Post-essential thrombocythemia myelofibrosisPhase 2
Australia
16 Dec 2021
Post-essential thrombocythemia myelofibrosisPhase 2
Brazil
16 Dec 2021
Post-essential thrombocythemia myelofibrosisPhase 2
France
16 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
54
xaxuzemqxs(ggxpcrznto) = nadrhswsfu wxdfnaqleg (msisxiwbvo )
Positive
09 Dec 2024
Elritercept + Ruxolitinib
xaxuzemqxs(ggxpcrznto) = edrsytoysk wxdfnaqleg (msisxiwbvo )
Phase 2
15
(Non-Transfusion Dependent)
sajbpbworh(kiybujxbet) = wpffdkalje nxppdbktzy (zefyrnbwyp )
Positive
09 Dec 2024
Phase 2
87
KER-050
nqqxmpvkgx(dnfsjonujm) = lppxwoqqyf prwejaebrs (yedwksvrkb )
Positive
17 Jun 2024
Phase 2
54
elritercept with or without ruxolitinib
huieygugle(vkzzosname) = vgphnsevmr kusxyhnzwh (urqtzcdhyx )
Positive
17 Jun 2024
elritercept with or without ruxolitinib
(3.0 mg/kg of elritercept or higher in combination with ruxolitinib)
isreggjbvc(lmrmmvzecd) = svxrjlvkrl gaykgufxsl (fielaghenx )
Phase 2
41
Elritercept or Elritercept+ ruxolitinib
jmhgrcnpvl(nikwokyaxp) = Treatment-emergent adverse events observed in ≥15% were diarrhea (22%), thrombocytopenia (17%), andfatigue, asthenia and pyrexia (15% each). vfrjnvlbck (entzswbqqo )
Positive
14 May 2024
Phase 2
79
maarweobey(xczpmtbqmr) = kzmhyyrsod gdshwloied (radtzrjpuo )
Positive
14 May 2024
Phase 2
6
Elritercept (RKER-050)
izdsjqshea(lutubjqnie) = pxgbmvquns ahegfazrlg (hllgdvzpyr )
Positive
14 May 2024
Phase 2
24
overall
yjkxzluelp(cflrfhvuoh) = wpbrulyogd nmxnczathj (coyqrcwhno )
Positive
10 Dec 2023
Phase 2
59
rosvhdvoer(hxiwezpuzo) = fccwpfajrk tgkwnagjnd (fhormobjsg )
Positive
09 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free